Ahead of the July 29 Advisory Committee: We Urge the FDA to Consider the Totality of Evidence

On July 29th, 2026, the FDA will convene an Advisory Committee meeting to evaluate Deramiocel, Capricor Therapeutics’ investigational therapy for Duchenne muscular dystrophy. These meetings are an important step in the regulatory process, bringing together... The post Ahead of the July 29 Advisory Committee: We Urge the FDA to Consider the Totality of Evidence appeared first on Parent Project Muscular Dystrophy .